TGO methodology overview

Testing is performed in alignment with applicable Therapeutic Goods Orders and Australian regulatory expectations for medicinal cannabis products.

Identity and composition testing

• Verification of product identity and consistency using validated analytical techniques
• Liquid Chromatography (LC)–based analysis for accurate cannabinoid profiling
• Support for TGO requirements related to product description and composition

Cannabinoid assays

• Quantitative determination of cannabinoids to support TGO limits and labeling claims
• High‑precision assays suitable for batch release and regulatory submission

Safety and quality testing

• Heavy metals analysis (including arsenic, cadmium, lead, and mercury)
• Moisture content determination to support product stability and shelf‑life expectations

All testing is conducted using validated methodologies appropriate for pharmaceutical‑grade medicinal cannabis products supplied to the Australian market. 

Why TGO compliance matters

• Market access requirement: TGO compliance is mandatory for medicinal cannabis supplied in Australia
• Pharmaceutical quality expectations: Aligns cannabis products with conventional therapeutic goods standards
• Labeling and content accuracy: Supports compliance with cannabinoid content and specification limits
• Regulatory confidence: Produces reliable data for submissions, audits, and ongoing market oversight

Meeting TGO requirements is critical for maintaining uninterrupted access to the Australian medical cannabis market.